MDCC Q4 Revenues Grow 43 Percent On Upstate Sale, Axon Integration | GenomeWeb

After expressing doubts about the health of the life sciences and drug-discovery markets last quarter, Molecular Devices last week took a more optimistic outlook on the two market segments as it reported revenue gains of 43 percent while nearly quadrupling its net income for the fourth quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.